Comment on Hadadi et al., Does recombinant human erythropoietin administration in critically ill COVID‐19 patients have miraculous therapeutic effects? J. Med. Virol. 2020; 92:915‐918

Therapeutic Effects ◽

Does recombinant human erythropoietin administration in critically ill COVID‐19 patients have miraculous therapeutic effects?

Journal of Medical Virology ◽

10.1002/jmv.25839 ◽

2020 ◽

Vol 92 (7) ◽

pp. 915-918 ◽

Cited By ~ 17

Author(s):

Azar Hadadi ◽

Masoud Mortezazadeh ◽

Kasra Kolahdouzan ◽

Golbarg Alavian

Keyword(s):

Critically Ill ◽

Therapeutic Effects ◽

Outcomes with the Use of Recombinant Human Erythropoietin in Critically Ill Burn Patients

Yearbook of Surgery ◽

10.1016/j.ysur.2011.04.052 ◽

2011 ◽

Vol 2011 ◽

pp. 71-72

Author(s):

D.W. Mozingo

Keyword(s):

Critically Ill ◽

Burn Patients ◽

Cost-Effectiveness of Recombinant Human Erythropoietin for Reducing Red Blood Cells Transfusions in Critically Ill Patients

Value in Health ◽

10.1111/j.1524-4733.2005.04006.x ◽

2005 ◽

Vol 8 (2) ◽

pp. 105-116 ◽

Cited By ~ 26

Author(s):

Robert MacLaren ◽

Patrick W. Sullivan

Keyword(s):

Cost Effectiveness ◽

Red Blood Cells ◽

Critically Ill ◽

Critically Ill Patients ◽

Blood Cells ◽

EFFICACY OF RECOMBINANT HUMAN ERYTHROPOIETIN IN THE CRITICALLY ILL PATIENT

Critical Care Medicine ◽

10.1097/00003246-199801001-00007 ◽

1998 ◽

Vol 26 (Supplement) ◽

pp. 23A ◽

Cited By ~ 3

Author(s):

Howard L Corwin ◽

Andrew Gettinger ◽

Robert M Rodriguez ◽

Ronald G Pearl ◽

Dean Gubler ◽

...

Keyword(s):

Critically Ill ◽

Critically Ill Patient ◽

Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial

Critical Care Medicine ◽

10.1097/00003246-199911000-00004 ◽

1999 ◽

Vol 27 (11) ◽

pp. 2346-2350 ◽

Cited By ~ 250

Author(s):

Howard L. Corwin ◽

Andrew Gettinger ◽

Robert M. Rodriguez ◽

Ronald G. Pearl ◽

K. Dean Gubler ◽

...

Keyword(s):

Critically Ill ◽

Controlled Trial ◽

Critically Ill Patient ◽

Double Blind ◽

Double Blind Placebo ◽

Best evidence in critical care medicine: The use of recombinant human erythropoietin to reduce red cell transfusions in critically ill patients

Canadian Journal of Anesthesia/Journal canadien d anesthésie ◽

10.1007/bf03018406 ◽

2004 ◽

Vol 51 (6) ◽

pp. 621-622 ◽

Cited By ~ 1

Author(s):

Osama Almuslim ◽

David Leasa

Keyword(s):

Critical Care ◽

Critically Ill ◽

Critically Ill Patients ◽

Critical Care Medicine ◽

Red Cell ◽

Efficacy of Recombinant Human Erythropoietin in Critically Ill Patients

JAMA ◽

10.1001/jama.288.22.2827 ◽

2002 ◽

Vol 288 (22) ◽

pp. 2827 ◽

Cited By ~ 346

Author(s):

Howard L. Corwin ◽

Andrew Gettinger ◽

Ronald G. Pearl ◽

Mitchell P. Fink ◽

Mitchell M. Levy ◽

...

Keyword(s):

Critically Ill ◽

Critically Ill Patients ◽

Recombinant Human Erythropoietin Use in a Critically Ill Jehovah’s Witness After Cardiac Surgery

Anesthesia & Analgesia ◽

10.1213/01.ane.0000159158.70532.d0 ◽

2005 ◽

Vol 101 (2) ◽

pp. 325-327 ◽

Cited By ~ 16

Author(s):

Susanna Price ◽

John R. Pepper ◽

Siân I. Jaggar

Keyword(s):

Cardiac Surgery ◽

Critically Ill ◽

Jehovah’S Witness ◽

Jehovah's Witness ◽

Number Needed to Treat and Cost of Recombinant Human Erythropoietin to Avoid One Transfusion-Related Adverse Event in Critically Ill Patients

Yearbook of Surgery ◽

10.1016/s0090-3671(08)70361-6 ◽

2006 ◽

Vol 2006 ◽

pp. 77-78

Author(s):

D.W. Mozingo

Keyword(s):

Adverse Event ◽

Critically Ill ◽

Critically Ill Patients ◽

Number Needed To Treat ◽

Related Adverse Event ◽

Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial*

Critical Care Medicine ◽

10.1097/00003246-200109001-00011 ◽

2001 ◽

Vol 29 (Supplement) ◽

pp. S201-S205 ◽

Cited By ~ 1

Author(s):

Howard L. Corwin ◽

Andrew Gettinger ◽

Robert M. Rodriguez ◽

Ronald G. Pearl ◽

K. Dean Gubler ◽

...

Keyword(s):

Critically Ill ◽

Controlled Trial ◽

Critically Ill Patient ◽

Double Blind ◽

Double Blind Placebo ◽